MicroRNAs in Testicular Cancer: Implications for Pathogenesis, Diagnosis, Prognosis and Therapy

ANGELIKA BEZAN¹, ARMIN GERGER¹ and MARTIN PICHLER¹,²

¹Division of Clinical Oncology, Medical University of Graz, Comprehensive Cancer Center Graz, Graz, Austria; ²Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, TX, U.S.A.

Abstract. Testicular germ cell tumors (TGCTs) represent the most common type of solid tumors among men aged 15 to 40 years. An increasing incidence has been recorded in developed countries. In clinical practice, TGCTs are classified as seminomas and non-seminomatous tumors. Non-seminomatous tumors often contain multiple different cell types and can be further sub-divided according to the histological and cellular phenotype in embryonal carcinomas, choriocarcinomas, yolk sac tumors and teratomas. For the clinical management of TGCTs, blood-based markers such as lactate dehydrogenase, alpha-fetoprotein and human chorionic gonadotropin are essential tools for diagnosis, risk assessment and patient’s prognosis. However, only 60% of patients with TGCTs show increased serum levels of these tumor markers. This proportion of patients is even lower for those with seminomas or pure embryonal carcinomas as alpha-fetoprotein is predominantly related to yolk sac tumor and human chorionic gonadotropin to choriocarcinoma.

Recently, small non-coding RNAs (microRNAs) were found to play a pivotal role in the process of malignant transformation in several types of cancers. By direct interaction with the larger messenger RNA molecules, microRNAs regulate the level of gene expression on a post-transcriptional level. MicroRNAs show great potential as novel biomarkers because they reveal high stability in body fluids, and they are easily and relatively inexpensive to detect by standard quantitative reverse transcriptase polymerase chain reaction assays. In the present review, we summarize the latest research findings regarding the role of microRNAs in the pathogenesis of TGCTs. In addition, we indicate their potential as diagnostic, prognostic and therapeutic biomolecules.

MicroRNAs

With growing knowledge about the human genome, it has become clear that less than 2% of the human genome consists of coding regions (exons) that are able to serve as a matrix for a respective messenger RNA (mRNA). This process of gene transcription in the nucleus is followed by the process of translation into a protein at the cytoplasmatic level (1). Until the early 1990s, the rest of the genome was thought to function as a buffer against genetic damage, without having any specific role (some researchers called these pieces of DNA ‘junk DNA’) (1). Within the last 20 years, more and more of the enigmatic role of this non-protein-coding genomic region has been resolved. New classes of RNA molecules, so called non-coding RNAs, have been identified as ‘new kids on the block’ (19).

In this context, a new class of non-coding RNAs, small regulatory RNAs (microRNAs, or miRNAs) were discovered (2). miRNAs have since been investigated in several thousands of studies and were found to play an important role as post-transcriptional regulators. Notably, they are not only involved in many physiological processes, such as cell differentiation, but also influence pathological processes, including carcinogenesis (7).

Considering some general aspects, miRNAs are normally transcribed by RNA polymerase II as primary transcripts pri-miRNA. Primary miRNAs form specific stem–loop structures and are cleaved in the nucleus by the RNase DROSHA into isolated hairpin loops (pre-miRNA) that are transported into the cytoplasm by the EXPORTIN 5 pore protein. In the cytoplasm, the loop is cleaved by the endoribonuclease DICER into mature miRNA. This molecule is single-stranded with a length of 19-22 nucleotides. Its specific sequence is known as the seed sequence (6, 7).
miRNAs bind to complementary sequences in the 3'-untranslated region (UTR) or other regions of their target mRNAs, usually resulting in gene silencing through the induction of mRNA degradation or inhibition of protein translation.

In mammalian cells, the hybridization of miRNA and target mRNA is non-perfect. It is believed that miRNAs are recognized by multiple miRNAs and the total number of interactions determines the inhibition of protein translation (22).

The non-perfect complementarity between miRNAs and protein-coding genes makes it difficult to pinpoint relevant downstream targets of individual miRNAs. Several algorithms were developed to predict putative miRNA targets such as miRanda, Pic Tar and Target Scans (35).

As miRNAs interfere with the translation of a given mRNA to a protein, they can act as tumor-suppressor genes or oncogenes. For example, in chronic lymphatic leukemia, miR-15 and miR-16 function as tumor suppressors, whereas the miR-17 to -92 cluster is found to be an oncogene in lung cancer (22).

The expression profiling of miRNAs can be informative regarding cancer prognosis and has been extensively shown in many cancer types, including chronic lymphatic leukemia, colorectal cancer, breast and kidney cancer (1, 30-33).

Furthermore, there have been attempts to use miRNAs as predictive factors for pharmacological response, medical treatment approaches and adverse side-effects of drugs (19), (3).

The aim of the present short review is to discuss the current insights of the involvement of miRNAs in the pathogenesis of testicular cancer. Furthermore, we highlight and describe their potential as novel diagnostic and prognostic biomarkers for future purposes in patients with testicular cancer.

**MicroRNAs and the Pathophysiology of Testicular Cancer**

**Testicular cancer and p53.** In most types of solid cancer, an inactivating mutation of the tumor suppressor gene p53 is found. One explanation is that one of the physiological functions of p53 is induction of senescence after oncogenic stress by inducing cellular arrest or apoptosis (35). In testicular germ cell tumors (TGCTs), inactivating mutations of p53 are rare events. Instead of a p53 mutation or deletion, miR-372 and miR-373 have been identified to be up-regulated in TGCTs (4, 5, 12, 29). These miRNAs have been shown to mimic the effects of mutated p53. In the rare cases of seminomas with a proven mutation of p53, a lack of up-regulation of this specific set of miRNAs was reported (22, 35).

Vorhooewe et al. have shown that cells transduced with miR-372 or miR-373 continue to proliferate after rat sarcoma viral oncogene homolog (RAS)-induced oncogenic stress, whereas control cells ceased proliferation. In the control cell group, following RAS stimulation, p53 is activated and its target gene p21 is induced. Increased levels of p21 inhibit cyclin-dependent kinase (CDK) activity, causing cells to arrest in G1 phase (10, 35).

miR-372 and miR-373 do not directly inhibit p53 activity. Indeed, their direct target is the large tumor suppressor homolog 2 (LATS2) gene. miR-372 and miR-373 bind to two sites in the 3' UTR of LATS2 and thereby suppress the translation of LATS2 mRNA. A reduction of LATS2 protein level seems to be responsible for the sustained activity of CDK, allowing uncontrolled cell proliferation (35).

**Testicular cancer and E2F Transcription factor.** The retinoblastoma tumor-suppressor protein exerts its tumor suppressive function by regulating the E2F Transcription factor (E2F) family of transcription factors.

miR-449a and miR-449b have been found to be up-regulated by E2F1 expression after DNA damage. miR-449a and -b structurally resemble miR-34, a well-known p53-responsive and pro-apoptotic miRNA. miR-449a and -b suppress cell proliferation by activation of a p53-induced mechanisms and probably also by p53-independent mechanisms. High miR-449 levels were found in normal testes, lung and trachea but were not detectable in testicular and other cancer cells (21).

**Epigenetic modulation in testicular cancer.** Epigenetic alteration is another proposed mechanism of carcinogenesis. In TGCTs, hypermethylation of the intronic region dynamine 3 (DNM3) at chromosome 1q24.3 leads to down-regulation of miR-199a(6). The target of miR-199a is the anti-adhesive transmembrane protein podocalyxin-like protein 1 (PODXL). PODXL is an anti-adhesion transmembrane protein that inhibits cell–cell interaction, which is causative for developing an invasive phenotype and metastasis (6). PODXL is highly expressed in malignant testicular tumor and negatively correlated with miR-199a expression. Hypermethylation of DNM3 leads to miR-199a depression and up-regulation of PODXL. miR-199a was also linked to other malignancies, including gastric cancer, bladder cancer, uveal melanoma and ovarian cancer (34).

In a xenograft mouse model, expression of miR-199a in cancer cells led to suppression of cancer migration, invasion and cell growth.

When comparing the different histological subtypes of testicular cancer it was found that miR-199a has a higher degree of methylation in seminomas than in non-seminomatous tumors (6).

**Male infertility and testicular cancer.** Infertile men are nearly three-times more likely to develop TGCTs than are those who are fertile (36). A possible connection between male infertility and TGCTs might be through a pathway which is
regulated by miR-383 (18). miR-383 expression is down-regulated in the testes of infertile men with maturation arrest. Down-regulation of miR-383 results in enhanced proliferative activity of germ cells. The direct target of miR-383 is the interferon regulatory factor-1 (IRF1) which has been identified as a tumor-suppressor gene. However, in spermatogonia and early spermatocytes, it seems to have a pro-mitogenic role. IRF1 is a downstream target of miR-383 and is negatively correlated with miR-383 expression. The inhibition of IRF1 leads to reduced levels of cyclin D1, CDK2 and p21. Cyclin D1 seems to be the major gene responsible for miR-383 mediated antiproliferative effects. Furthermore, ectopic expression of miR-383 leads to a decrease in CDK4 expression. The cyclin D1–CDK4–p21 complex leads to phosphorylation and inactivation of the retinoblastoma tumor-suppressor protein (pRb).

Thus, miR-383 is a negative regulator of proliferation by targeting IRF1 and through inactivation of the pRb pathway (18).

**Diagnosis**

TGCTs arise from carcinoma *in situ* cells which resemble malignant primordial germ cells of fetal origin (15, 24). They persist in the testis until puberty or early adulthood and will then progress in either seminoma (which generally do not differentiate) or non-seminomatous tumors.

Carcinoma *in situ* cells exhibit a gene expression pattern similar to that of embryonic stem cells, which explains their pluripotency. They can form the germ cell lineage (seminoma) or embryonal stem cell components (embryonal carcinoma), with possible further differentiation to choriocarcinoma, yolk sac tumors or teratoma (16, 27, 28). As miRNAs regulate cell differentiation and other physiological processes, it has been supposed that in cases of malignant transformation, the miRNA profile changes. Several studies indicate that miRNAs are involved in this critical step of carcinogenesis (11, 12).

For instance, in seminoma a significant difference in miRNA expression was found when compared with normal testicular tissue. miRNA-221, miR-222, miR-372 and miR-374 are up-regulated in seminoma whereas other miRs including miR-30a, miR-34a, miR-99, miR-105-1.2, miR-106a, miR-293, miR-217, miR-196-1, and miR-196-2 are down-regulated.

In addition, expression profiling of miRNAs can also be used for differentiation of the major histological subtypes of TGCTs (12, 22, 23).

The miR-302 cluster is expressed in human embryonic stem cells and therefore in embryonal carcinoma and seminoma also (11, 12). With differentiation of embryonal carcinomas to teratomas, the expression of miR-302 cluster is down-regulated. The same expression pattern is found for miR-17-5p and miR-154. They are expressed in embryonal carcinoma and down-regulated upon differentiation to teratomas (12), miR-301 is predominantly found in the more differentiated tissues, such as spermatocytic seminomas, yolk sac tumors and teratomas, whereas miR-301 is absent from embryonic stem cells and embryonal carcinoma (12).

As mentioned in the chapter of "MicroRNAs and the pathophysiology of Testicular cancer", the miR-371 to miR-373 cluster is expressed in seminomas, embryonal carcinomas, yolk sac tumors and is related to wild-type p53 status (22, 23, 12).

**Monitoring**

After tumor tissue-specific miRNAs were identified in the serum of patients, the idea was born that miRNAs could qualify as circulating biomarkers, a concept that is well-known for other molecular components such as circulating tumor cells or circulating free DNA (14, 25, 26, 37), (13).

In a prospective study by Dieckmann *et al.*, serum levels of miRNA-371 to -373 from 24 patients with TGCTs (20 seminoma, four non-seminomatous tumors) were quantified by reverse transcriptase polymerase chain reaction (8). Out of the three miRNAs quantified, miR-371a-3p showed the most impressive result as considerably high expression was revealed in treatment-naïve patients, with a strong decline after surgical removal of the tumor. In this study, 20 patients presented with clinical stage I disease. Only 25% showed elevation of the classical markers (alpha-fetoprotein, human chorionic gonadotropin), whereas 85% of patients had a higher level of miRNA-371a-3p when compared with the mean value of healthy controls. Moreover, in stage I disease, the serum level of miRNA 371a-3p decreased significantly after orchiectomy (a 336.7-fold reduction). In four patients with advanced disease serum levels of miRNA-371a-3p dropped into normal range of the control population after completion of chemotherapy treatment. Interestingly, neither a correlation between miRNA expression level in tumor tissue and serum, nor a correlation with the extent of tumor volume was observed (8).

In another study, Gillis *et al.* compared serum levels of miR-371 to -373, miR-302 and miR-367 from 80 patients with TGCTs with those of 47 healthy controls. miR-371 to -373 and miR-367 showed the most promising results. By combining these miRNAs, a clear separation of tumor from control samples was possible. The miRNAs had an overall sensitivity of 98%, whereas the traditional serum markers alpha-fetoprotein/human chorionic gonadotropin revealed only a sensitivity of 36%/57%, which was even lower when applied for seminomas alone (11).

These results underline the superiority of miRNAs for diagnosis and monitoring of stem cell components when compared to traditional markers.

Further studies with larger patient cohorts are warranted to confirm these promising first results.
**Prognosis and Treatment**

TGCTs respond well to chemotherapy and more than 80% of patients with metastatic TGCTs are curable using a cisplatin-based first-line chemotherapy (9). It is supposed that this high cure rate might be related to elevated wild-type p53 function in TGCTs or high levels of the pro-apoptotic BCL2-associated X protein (BAX) and low levels of the anti-apoptotic BCL2 protein (high BAX:BCL2 ratio).

When comparing TGCT cell lines with somatic cell lines after cisplatin exposure, differential gene expression was identified (9). For miR-372 to -373, which have frequently been reported to be overexpressed in TGCTs, around 40 target genes were identified. Neogenin homolog 1 (NEO1), LATS2 and estrogen receptor 1 (ESR1) were the only genes that have the predicted binding sites for both p53 and miR-372 to -373. NEO1 and LATS2 were down-regulated in GCT cells after cisplatin exposure, while ESR1 was up-regulated (9).

Another reason for an altered expression of miR-372 to -373 targeted genes might be the down-regulation of the endoribonuclease DICER1 gene after cisplatin exposure. Loss of DICER1 was reported to cause embryonic lethality and loss of stem cell population. Cisplatin-induced down-regulation of DICER1 may repress the oncogenic functions of miR-372 to -373 (9).

Several studies have shown that aberrant miRNA expression is related to overall survival, disease stage and the development of metastases and disease recurrences (1, 32).

Moreover, expression levels of miRNA-302a have been associated with increased sensitivity of TGCTs to cisplatin. Up-regulation of miRNA-302 enhances cisplatin-induced G2/M phase arrest and subsequent apoptosis (20).

On the other hand, cisplatin resistance has been associated with high levels of cytoplasmatic p21. miR-106b seed family members regulate p21 expression levels. Octamer binding transposition factor 4 (OCT4) regulates the expression level of miR-106b. OCT3/4 are markers of pluripotency and are therefore expressed in embryonic stem cells and TGCTs but not in mature teratomas (17, 22).

Cisplatin-resistant cells have lower levels of OCT4 and miR-106b family members, and high amounts of cytoplasmatic p21, resulting in CDK2 inhibition and prevention of cisplatin-induced apoptosis. Cytoplasmatic localization of p21 can be caused by phosphorylation of p21. Phosphorylation of p21 is mediated through protein kinase B (pAKT). Deactivation of AKT via the phosphoinositide 3-kinase (PI3K) inhibitor LY294002 or with the specific AKT inhibitor triciribine leads to nuclear localization of p21, which in turn is no longer capable of blocking cisplatin-induced apoptosis (17).

Germ cell tumors often represent curative disease, including advanced disease stages, when treated with chemotherapy. Nevertheless, short- and long-term side-effects such an infertility, renal impairment, lung toxicity and others, can occur from chemotherapy. Improved prognostic tools are needed to categorize the risk of the individual patient in order to minimize such effects of treatment. miRNAs seem to have great potential as diagnostic, prognostic and, ultimately, therapeutic biomolecules in this future perspective.

**References**


